These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23016521)

  • 1. Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users.
    Verhoef TI; Redekop WK; Hegazy H; de Boer A; Maitland-van der Zee AH;
    J Thromb Haemost; 2012 Dec; 10(12):2610-2. PubMed ID: 23016521
    [No Abstract]   [Full Text] [Related]  

  • 2. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
    van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
    J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
    Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy.
    Luxembourg B; Schneider K; Sittinger K; Toennes SW; Seifried E; Lindhoff-Last E; Oldenburg J; Geisen C
    Thromb Haemost; 2011 Jan; 105(1):169-80. PubMed ID: 21057703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
    Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
    Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
    Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
    Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes.
    Qazim B; Stöllberger C; Krugluger W; Dossenbach-Glaninger A; Finsterer J
    J Thromb Thrombolysis; 2009 Aug; 28(2):211-4. PubMed ID: 18629445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing.
    Werner D; Werner U; Wuerfel A; Grosch A; Lestin HG; Eschenhagen T; Rau T
    Eur J Clin Pharmacol; 2009 Aug; 65(8):783-8. PubMed ID: 19319511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
    Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
    Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.
    Mannucci PM; Spreafico M; Peyvandi F
    J Thromb Haemost; 2008 Sep; 6(9):1450-2. PubMed ID: 18627441
    [No Abstract]   [Full Text] [Related]  

  • 15. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetics of indirect anticoagulants: value of genotype for improvement of efficacy and safety of therapy].
    Sychov DA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
    Kardiologiia; 2006; 46(7):72-7. PubMed ID: 16883270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.
    Abduljalil K; Lazar S; Natanzon M; Wu W; Zadoyan G; Steffens B; Kohl V; Mörike K; Tomalik-Scharte D; Stingl J; Schwab M; Harenberg J; Gleiter C; Fuhr U
    Clin Pharmacokinet; 2013 May; 52(5):359-71. PubMed ID: 23519598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis.
    Pasmant E; de Beauvoir C; Plessier A; Labreuche J; Bezeaud A
    Thromb Res; 2010 Aug; 126(2):e134-6. PubMed ID: 20434758
    [No Abstract]   [Full Text] [Related]  

  • 19. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population.
    Silan C; Dogan OT; Silan F; Kukulguven FM; Asgun HF; Ozdemir S; Uludag A; Atik S; Gungor B; Akdur S; Aksulu HE; Ozdemir O
    Mol Biol Rep; 2012 Dec; 39(12):11017-22. PubMed ID: 23065265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.